2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-Site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead.
Baxter, E.W., Conway, K.A., Kennis, L., Bischoff, F., Mercken, M.H., Winter, H.L., Reynolds, C.H., Tounge, B.A., Luo, C., Scott, M.K., Huang, Y., Braeken, M., Pieters, S.M., Berthelot, D.J., Masure, S., Bruinzeel, W.D., Jordan, A.D., Parker, M.H., Boyd, R.E., Qu, J., Alexander, R.S., Brenneman, D.E., Reitz, A.B.(2007) J Med Chem 50: 4261-4264
- PubMed: 17685503 
- DOI: https://doi.org/10.1021/jm0705408
- Primary Citation of Related Structures:  
2Q11, 2Q15 - PubMed Abstract: 
A new aspartic protease inhibitory chemotype bearing a 2-amino-3,4-dihydroquinazoline ring was identified by high-throughput screening for the inhibition of BACE-1. X-ray crystallography revealed that the exocyclic amino group participated in a hydrogen bonding array with the two catalytic aspartic acids of BACE-1 (Asp(32), Asp(228)). BACE-1 inhibitory potency was increased (0.9 microM to 11 nM K(i)) by substitution into the unoccupied S(1)' pocket.
Organizational Affiliation: 
Johnson & Johnson Pharmaceutical Research and Development, LLC, Spring House, Pennsylvania 19477, USA. ebaxter@prdus.jnj.com